Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Medulloblastoma 2Glioblastoma 2Ependymoma 2Brain Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Irinotecan 30Gemcitabine 25Paclitaxel 24Cisplatin 24Docetaxel 19Oxaliplatin 15Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 12Capecitabine 12Bortezomib 10Taxes 83-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Topotecan 6Temozolomide 6Immunohistochemistry 6Immunoenzyme Techniques 6Bevacizumab 67-hydroxystaurosporine 6tanespimycin 5Sorafenib 5Pharmacogenomic Testing 5Pemetrexed 5Etoposide 5Chromatography, High Pressure Liquid 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unspecified Adult Solid Tumor, Protocol Specific × 1-methyltryptophan × Clear all
NCT00567931 2014-07-24

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
52 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01191216 2014-07-24

1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡